Clinical trials: Gram-negative Bacterial Infection
Infections, Meningococcal
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK Biologicals' meningococcal vaccine GSK134612 as compared to Menactra® in adolescents/adults 11-25 years of age.
- Trial name
- NCT00454909
- Testing
- Meningococcal vaccine 134612, Menactra®
- Where
- 10 sites in United States
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diarrhoea
A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants
This study evaluates the immune response and safety of a multicomponent, 2-dose Shigella vaccine in preventing shigellosis in African infants.
- Trial name
- NCT06663436
- Testing
- altSonflex1-2-3 Dose A, altSonflex1-2-3 Dose B, altSonflex1-2-3 Dose C
- Where
- Kenya
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dysentery, Dysentery, Bacillary
Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
The purpose of this study is to evaluate safety of S.flexneriza-S.sonnei Bivalent Conjugate Vaccine in healthy volunteers aged above 3 Months.
- Trial name
- NCT03561181
- Testing
- S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Campylobacter Infection
ACE393-103 Vaccination Challenge Study
The purpose of this study is to determine whether ACE393 vaccination can protect against Campylobacteriosis in a challenge model.
- Trial name
- ACE393-103VC (NCT00859716)
- Testing
- ACE393
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- TD Vaccines A/S
Meningococcal Disease
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea
A multicenter, single arm, post-marketing surveillance study. This study is a postlicensure requirement of the Korea Food and Drug Administration (KFDA) to provide continued safety evaluation of MenACWY in the Korean population…
- Trial name
- NCT01766206
- Testing
- MenACWY-CRM (Menveo)
- Where
- 54 sites in South Korea
- Volunteers
- 3,948 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease; Meningococcal Meningitis
Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine
The purpose of this study is to determine when a memory immune response after re-vaccination with Meningococcal C conjugate vaccine (Menjugate) or challenge with Meningococcal A/C polysaccharide vaccine can be observed, after…
- Trial name
- NCT00262015
- Testing
- · Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)
- Where
- United Kingdom
- Volunteers
- 264 people
- Sponsor
- Chiron Corporation
Meningitis, Meningococcal Meningitis
Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation
The aim of this study is to generate local data on the safety of Menactra® in individuals 2 to 55 years of age in the Russian Federation.
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT02699840
- Testing
- Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tetanus, Diphtheria
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
The aim of this study is to describe immunogenicity of a single booster dose of Adacel vaccine versus Boostrix vaccine among approximately 420 adolescents 11 to <13 years of age.
- Conditions
- Tetanus, Diphtheria, Pertussis, Whooping Cough
- Trial name
- NCT01629589
- Testing
- Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)
- Where
- 8 sites in United States
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Bordetella Infections, Bordetella Pertussis Infection
A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic Patients
A three-arm, multi-site clinical evaluation of the ARIES Bordetella Assay for the detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B.
- Conditions
- Bordetella Infections, Bordetella Pertussis Infection, Bordetella Parapertussis Infection
- Trial name
- NCT02862262
- Testing
- ARIES Bordetella Assay
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,052 people
- Sponsor
- Luminex Molecular Diagnostics
Diphtheria, Acellular Pertussis
Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants
The purpose of this study is to assess the immunogenicity and safety of DTPa-IPV/Hib when administered at 6, 10 and 14 weeks to healthy Indian infants, as per guidance from the Indian regulatory authority.
- Conditions
- Diphtheria, Acellular Pertussis, Haemophilus Influenzae Type b, Tetanus
- Trial name
- NCT03128489
- Testing
- Infanrix-IPV/Hib
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers (Meningococcal Infection)
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
The primary objective of this study is to demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following administration of 2 doses of MenACYW conjugate vaccine compared to 2 doses…
- Trial name
- NCT03691610
- Testing
- Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Disease, Meningococcal Meningitis
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
This study is designed to evaluate the immunogenicity and the safety of a quadrivalent vaccine MenACWY-CRM in healthy subjects from 11 to 55 years of age in Korea.
- Trial name
- NCT01274897
- Testing
- Novartis MenACWY-CRM
- Where
- 8 sites in South Korea
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Meningitis
A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine
Safety Evaluation of freeze-dried Group ACYW135 Meningococcal conjugate vaccine in healthy people above 2-months-old
- Trial name
- NCT02481232
- Testing
- freeze-dried group ACYW135 MCV
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Neisseria Meningitides Meningitis
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
This is a phase IV, single-center, observer-blind, randomized, controlled vaccine trial in 2 to 10 years old healthy subjects. Each participant will receive a single intramuscular injection of one of the two vaccines either MPV…
- Trial name
- NCT04450498
- Testing
- Yuxi Walvax MPV ACYW® vaccine, Sanofi Pasteur Menactra® vaccine
- Where
- Mali
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Haemophilus Influenzae, Streptococcus Pneumoniae
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease.
- Trial name
- NCT00849069
- Testing
- GSK2231395A, TwinrixTM
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Diphtheria, Pertussis
Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®
PR5I, a hexavalent pediatric combination vaccine is being developed to reduce the number of injections during the first 2 years of life while providing a complete course of immunization against infection caused by H.
- Conditions
- Diphtheria, Pertussis, Polio, Hepatitis B
- Trial name
- NCT00362427
- Testing
- Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC
- Where
- 8 sites in Canada
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV Infections, Gonorrhea
Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
The objective of the study is to determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels compared to placebo in preventing vaginally acquired HIV infection.
- Conditions
- HIV Infections, Gonorrhea, Chlamydial Infections, Genital Herpes
- Trial name
- NCT00262106
- Testing
- PRO 2000/5
- Where
- 6 sites in South Africa, Tanzania and 2 more
- Volunteers
- 9,404 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Cystic Fibrosis, CF
Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
This is multicenter placebo-controlled study evaluating the safety and efficacy of AI at two dosage levels compared to placebo in CF patients with P. aeruginosa lung infection.
- Conditions
- Cystic Fibrosis, CF, Lung Infection, Pseudomonas Aeruginosa
- Trial name
- NCT01055847
- Testing
- Aztreonam for Inhalation (AI)
- Where
- 20 sites in United States
- Volunteers
- 105 people
- Sponsor
- Gilead Sciences
Infections, Meningococcal
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects
The purpose of this study is to demonstrate, in 11-17 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.
- Trial name
- NCT00464815
- Testing
- Meningococcal vaccine GSK134612, Mencevax™ ACWY
- Where
- 7 sites in India, Philippines and 1 more
- Volunteers
- 1,025 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cholera
Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera
Cholera still remains a global public health concern affecting both children and adults, and patients can succumb in quick time if remain untreated.
- Trial name
- NCT06193408
- Testing
- VR-AD-1005
- Where
- Bangladesh
- Volunteers
- 150 people
- Sponsor
- Hunazine Biotech S.L.